Nadunolimab
- Generic Name
- Nadunolimab
- Drug Type
- Biotech
- Unique Ingredient Identifier
- ND296JF21I
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- Conditions
- Myelodysplastic Syndrome(MDS)Acute Myelogenous Leukemia (AML)
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06548230
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 117
- Registration Number
- NCT05181462
- Locations
- 🇪🇸
Hospital Universitario Virgen de las Nieves, Granada, Andalucía, Spain
🇪🇸Hospital Universitario Clinico San Cecilio, Granada, Andalucía, Spain
🇪🇸Complejo Hospitalario de Jaén, Jaén, Andalucía, Spain
A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 25
- Registration Number
- NCT04990037
- Locations
- 🇪🇸
ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona, Spain
🇫🇷EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS, Rennes, France
🇫🇷EDOG - Institut Bergonie - PPDS, Bordeaux, France
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
- Conditions
- Carcinoma, Non-Small-Cell LungUrothelial CarcinomaHead and Neck Squamous Cell CarcinomaMalignant Melanoma
- Interventions
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 19
- Registration Number
- NCT04452214
- Locations
- 🇺🇸
Florida Cancer Specialists & Research Institute, Lake Mary, Florida, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.